ContractRegistration Rights Agreement • March 23rd, 2016 • Fluoropharma Medical, Inc. • In vitro & in vivo diagnostic substances
COMMON STOCK PURCHASE WARRANT FLUOROPHARMA MEDICAL, INC.Fluoropharma Medical, Inc. • January 7th, 2014 • In vitro & in vivo diagnostic substances
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [_____________] or its assigns or successors in interest (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to the close of business on the five year anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from FluoroPharma Medical, Inc., a Nevada corporation (the “Company”), up to [________] shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price (as defined in Section 2(c) hereof).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • June 24th, 2011 • Fluoropharma Medical, Inc. • Sanitary services • New York
THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of June 22, 2011, by and among, FluoroPharma Medical, Inc., a Nevada corporation (the “Company”), and those investors of the Company set forth on the signature pages to this Agreement (the “Purchasers” or sometimes the “Holders”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • September 19th, 2013 • Fluoropharma Medical, Inc. • In vitro & in vivo diagnostic substances • New York
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • November 21st, 2012 • Fluoropharma Medical, Inc. • In vitro & in vivo diagnostic substances • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of November 19, 2012, between FluoroPharma Medical, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
NOTE PURCHASE AGREEMENTNote Purchase Agreement • March 15th, 2017 • Fluoropharma Medical, Inc. • In vitro & in vivo diagnostic substances • New York
THIS NOTE PURCHASE AGREEMENT (this “Agreement”), is dated as of February __, 2017, by and between FluoroPharma Medical, Inc., a Nevada corporation (the “Company”), and the Purchasers identified on Schedule 1 hereto (the “Purchasers”).
NOTE AND WARRANT PURCHASE AGREEMENTNote and Warrant Purchase Agreement • June 3rd, 2015 • Fluoropharma Medical, Inc. • In vitro & in vivo diagnostic substances • New York
THIS NOTE AND WARRANT PURCHASE AGREEMENT (this “Agreement”), is dated as of May ___, 2015, by and between FluoroPharma Medical, Inc., a Nevada corporation (the “Company”), and the Purchasers identified on Schedule 1 hereto (the “Purchasers”).
SUBSCRIPTION AGREEMENTSubscription Agreement • June 24th, 2011 • Fluoropharma Medical, Inc. • Sanitary services • New York
THIS SUBSCRIPTION AGREEMENT (this “Agreement”) is made and entered into as of June 22, 2011, between FluoroPharma Medical, Inc., a Nevada corporation (the “Company”), and the investors identified on the signature page to this Agreement (the “Investors”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • January 7th, 2014 • Fluoropharma Medical, Inc. • In vitro & in vivo diagnostic substances • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of December 31, 2013, between FluoroPharma Medical, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
EXCLUSIVE LICENSING AND DISTRIBUTION AGREEMENTExclusive Licensing and Distribution Agreement • June 9th, 2016 • Fluoropharma Medical, Inc. • In vitro & in vivo diagnostic substances • Massachusetts
This Exclusive Licensing and Distribution Agreement (“Agreement”) is entered into and effective as of June 03, 2016 (“Effective Date”), by and between FluoroPharma Medical, Inc., a company organized and existing under the laws of Nevada, with its principal place of business located at 8 Hillside Avenue, Suite 207, Montclair, New Jersey, U.S., (“FluoroPharma”) and Sinotau USA, Inc. (a subsidiary of Sinotau Pharmaceutical Group, Chinese Name: 北京先通国际医药科技股份有限公司, i.e. Beijing Xiantong Guoji Yiyao Keji Gufen Youxian Gongsi a company organized and existing under the laws of the People’s Republic of China with registered address at Room 6168, #1 Building, #2 Courtyard, Heng Fu Middle Street, Science City, Fengtai District, Beijing China) a company organized under the laws of Delaware, with its principal place of business located at 27 Drydock Avenue, STE 7, Boston, Massachusetts, U.S. (“Sinotau”). FluoroPharma and Sinotau are each referred to herein by name or as a “Party” or, collectively, as
CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND MARKED WITH “[*******]” OR OTHERWISE CLEARLY INDICATED. AN UNREDACTED VERSION OF THIS DOCUMENT HAS ALSO BEEN PROVIDED TO THE SECURITIES...License Agreement • July 1st, 2014 • Fluoropharma Medical, Inc. • In vitro & in vivo diagnostic substances • Massachusetts
This License Agreement (“Agreement”) is made as of the First day of June 2014 (“Effective Date”), by and between The General Hospital Corporation, d/b/a Massachusetts General Hospital, a not-for-profit Massachusetts corporation, with a principal place of business at 55 Fruit Street, Boston, Massachusetts 02114 (“Hospital”) and FluoroPharma Medical, Inc., a Delaware corporation having a principal place of business at 8 Hillside Avenue, Suite 207, Montclair, New Jersey 07043 (“Company”), each referred to herein individually as a “Party” and collectively as the “Parties.”
ContractEmployment Agreement • October 8th, 2015 • Fluoropharma Medical, Inc. • In vitro & in vivo diagnostic substances • New Jersey
AGREEMENT AND PLAN OF MERGER FLUOROPHARMA MEDICAL, INC. FPI MERGER CORPORATION AND FLUOROPHARMA, INC. Dated as of May 13, 2011Agreement and Plan of Merger • July 12th, 2011 • Fluoropharma Medical, Inc. • Sanitary services • Delaware
This AGREEMENT AND PLAN OF MERGER (“Agreement”) made this 13th day of May, 2011, is entered into by and among FluoroPharma Medical, Inc., a Nevada corporation (“FPM”), FPI Merger Corporation, a Delaware corporation and wholly-owned subsidiary of FPM (“MergerCo”), and FluoroPharma, Inc., a Delaware corporation (“FPI”). FPM, MergerCo and FPI are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
LEASE AGREEMENT BY AND BETWEEN HILLSIDE SQUARE LLC, LESSOR, -and- FLOUROPHARMA, INC., LESSEE LEASED PREMISES: HILLSIDE SQUARE SUITE 207 MONTCLAIR, NEW JERSEY 07042Lease Agreement • November 14th, 2011 • Fluoropharma Medical, Inc. • In vitro & in vivo diagnostic substances
THIS LEASE AGREEMENT is made this 8th day of September, 2011 by and between HILLSIDE SQUARE LLC, a New Jersey limited liability company (“Lessor”) whose address is c/o The Bravitas Group, 105 Grove Street, Montclair, New Jersey 07042, and FLOUROPHARMA, INC., a corporation (“Lessee”), whose principal office is located at 500 Boylston Street, Suite 1600, Boston, Massachusetts 02116. .
AMENDMENT TO EMPLOYMENT AGREEMENTEmployment Agreement • April 15th, 2013 • Fluoropharma Medical, Inc. • In vitro & in vivo diagnostic substances • New Jersey
THIS IS AMENDMENT NO. 1 TO THE EMPLOYMENT AGREEMENT, entered into as of April 9, 2013, by and between FluoroPharma Medical, Inc., a Nevada corporation (the “Company”), and Johan M. (Thijs) Spoor (the “Executive”) (the “Agreement”).
EMPLOYMENT AGREEMENTEmployment Agreement • August 22nd, 2012 • Fluoropharma Medical, Inc. • In vitro & in vivo diagnostic substances • New Jersey
This EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of the 22nd day of August 2012, by and between FluoroPharma Medical, Inc., a Delaware corporation with offices at 8 Hillside Avenue, Suite 207, Montclair, NJ 07042 (the “Company”), and Tamara Rhein, an individual residing at __________ (“Executive”).
AMENDMENT NO. 5 TO PROMISSORY NOTE OF FLUOROPHARMA MEDICAL, INC.Fluoropharma Medical, Inc. • March 15th, 2017 • In vitro & in vivo diagnostic substances • New York
THIS AMENDMENT NO. 5 TO PROMISSORY NOTE OF FLUOROPHARMA MEDICAL, INC. (this “Amendment”), dated as of January 22, 2017, is made by FluoroPharma Medical, Inc., a Nevada corporation (the “Company” or the “Borrower”), and the undersigned holders (each, a “Holder” and, collectively, the “Holders”). The Company and the Holders are sometimes referred to individually as “Party” and collectively as the “Parties”.
WAIVERWaiver • March 2nd, 2017 • Fluoropharma Medical, Inc. • In vitro & in vivo diagnostic substances • New York
This waiver (this “Waiver”) is granted as of February [21], 2017, by Platinum-Montaur Life Sciences, LLC, a Delaware limited liability company (“Platinum Montaur”) in favor of FluoroPharma Medical, Inc., a Nevada corporation (the “Company”). Capitalized terms used but not defined herein shall have the meaning given to such term in the Purchase Agreement and the Warrant (each, as defined below), as applicable.
SECOND AMENDMENT TO LEASELease • March 31st, 2015 • Fluoropharma Medical, Inc. • In vitro & in vivo diagnostic substances
THIS SECOND AMENDMENT TO LEASE is made as of the day of February, 2015 by and between HILLSIDE SQUARE LLC, a New Jersey limited liability company (“Lessor”) whose address is c/o The Bravitas Group, 105 Grove Street, Montclair, New Jersey 07042, and FLOUROPHARMA, INC., a corporation (“Lessee”), having an office located at 8 Hillside Avenue, Montclair, New Jersey 07042.
ADDENDUM TO LEASE AGREEMENT This form approved by the Minnesota Association of REALTORS, which disclaims any liability arising out of use or misuse of this form.Lease Agreement • January 23rd, 2008 • Commercial E-Waste Management Inc • Sanitary services
AMENDMENT NO. 2 TO CONVERTIBLE PROMISSORY NOTE OF FLUOROPHARMA MEDICAL, INC.Fluoropharma Medical, Inc. • May 31st, 2016 • In vitro & in vivo diagnostic substances • New York
THIS AMENDMENT NO. 2 TO CONVERTIBLE PROMISSORY NOTE OF FLUOROPHARMA MEDICAL, INC. (this “Amendment”), dated as of May 26, 2016, is made by FluoroPharma Medical, Inc., a Nevada corporation (the “Company” or the “Borrower”), and the undersigned holders (each, a “Holder” and, collectively, the “Holders”). The Company and the Holders are sometimes referred to individually as “Party” and collectively as the “Parties”.
COMMON STOCK PURCHASE WARRANT FLUOROPHARMA MEDICAL, INC.Fluoropharma Medical, Inc. • June 3rd, 2015 • In vitro & in vivo diagnostic substances • New York
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [_____________] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to [______], 2020 [the date that is five years following the final Closing Date under the Purchase Agreement] (the “Termination Date”), but not thereafter, to subscribe for and purchase from FluoroPharma Medical, Inc., a Nevada corporation (the “Company”), up to [________] shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(c).
LEASE AGREEMENTLease Agreement • January 23rd, 2008 • Commercial E-Waste Management Inc • Sanitary services • Minnesota
THIS LEASE AGREEMENT made and entered into this 12th day of February, 2007 by and between 806 4th Street, LLC, a Minnesota Limited Liability Company (hereinafter referred to as the "LANDLORD"), and Commercial E-Waste Management, Inc., a Nevada Corporation (hereinafter referred to as the "TENANT").
SECURITY AGREEMENTSecurity Agreement • March 15th, 2017 • Fluoropharma Medical, Inc. • In vitro & in vivo diagnostic substances • Nevada
THIS SECURITY AGREEMENT is entered into as of February __, 2016 (the “Security Agreement”), by and between the undersigned creditors (“Creditors”), and FLUOROPHARMA MEDICAL, INC., a Nevada corporation, located at 8 Hillside Avenue, Suite 108, Montclair, NJ 07042 (the “Borrower”).
FLUOROPHARMA, INC.Letter Agreement • November 14th, 2011 • Fluoropharma Medical, Inc. • In vitro & in vivo diagnostic substances
Position and Duties. Upon your acceptance of this offer, you will serve as the President and Chief Executive Officer of FluoroPharma commencing on May 1, 2011, and continuing thereafter at the pleasure of the Board of Directors. As President and Chief Executive Officer, you will be responsible for overseeing the business and financial affairs of FluoroPharma under the direction of the Board of the Directors, and will report directly to the Board of Directors. You will be a part-time employee of FluoroPharma until such time as FluoroPharma shall have closed on its current round of funding. You will manage your time commitments consistent with your obligations to FluoroPharma. You join the Board of Directors of FluoroPharma.
ContractEmployment Agreement • October 8th, 2015 • Fluoropharma Medical, Inc. • In vitro & in vivo diagnostic substances • New Jersey
OFFICE USE AGREEMENTOffice Use Agreement • November 14th, 2011 • Fluoropharma Medical, Inc. • In vitro & in vivo diagnostic substances • Massachusetts
This Agreement is by and between PureTech Ventures, LLC ("PureTech") and FluoroPharma Medical, Inc. ("FluoroPharma") as of June 22, 2011 the ("Effective Date").
AMENDMENT TO LICENSE AGREEMENT Agreement Number: A220395.01 MGH Case Number: 02390License Agreement • August 15th, 2016 • Fluoropharma Medical, Inc. • In vitro & in vivo diagnostic substances • Delaware
THIS Amendment to the license agreement (the “Amendment”) is effective as of June 1, 2016 (“Amendment Effective Date”), by and between The General Hospital Corporation d/b/a Massachusetts General Hospital, a Not-For-Profit Massachusetts Corporation having a principal place of business at 55 Fruit Street, Boston, Massachusetts 02114 (“Hospital”) and FluoroPharma Medical, Inc., a Delaware corporation, having a principal place of business at 8 Hillside Avenue, Suite 207, Montclair, New Jersey 070433 (“Company”), each referred to herein individually as a “Party” or collectively as the “Parties”.
INDEPENDENT CONSULTING AGREEMENTIndependent Consulting Agreement • March 25th, 2014 • Fluoropharma Medical, Inc. • In vitro & in vivo diagnostic substances • New York
This Independent Consulting Agreement (“Agreement”), effective as of March 6, 2014 (“Effective Date”) is entered into by and between FLUOROPHARMA MEDICAL, INC., a Nevada corporation (herein referred to as the “Company”), and THE DEL MAR CONSULTING GROUP, INC., a California corporation and ALEX PARTNERS, LLC, a Washington State Limited Liability Corporation (collectively hereinafter referred to as the “Consultants” and each a “Consultant”), is dated as of March 24, 2014.
ContractFluoropharma Medical, Inc. • January 25th, 2016 • In vitro & in vivo diagnostic substances • New York
FluoroPharma Enters Development and Commercialization Agreement for China and CanadaCommercialization Agreement • June 9th, 2016 • Fluoropharma Medical, Inc. • In vitro & in vivo diagnostic substances
FluoroPharma Medical Inc. (OTCQB: FPMI) has entered an exclusive agreement with Sinotau USA Inc., a wholly owned subsidiary of Sinotau Pharmaceutical Group, a pharmaceutical enterprise with a focus on critical therapeutic areas. With this agreement, Sinotau will develop and commercialize FluoroPharma’s proprietary cardiac imaging assets CardioPET and BFPET in China and Canada. These agents address two different aspects of cardiovascular disease (CVD) with Positron Emission Tomography (PET) imaging.
AMENDMENT NO. 3 TO CONVERTIBLE PROMISSORY NOTE OF FLUOROPHARMA MEDICAL, INC.Fluoropharma Medical, Inc. • December 5th, 2016 • In vitro & in vivo diagnostic substances • New York
THIS AMENDMENT NO. 3 TO CONVERTIBLE PROMISSORY NOTE OF FLUOROPHARMA MEDICAL, INC. (this “Amendment”), dated as of November __, 2016, is made by FluoroPharma Medical, Inc., a Nevada corporation (the “Company” or the “Borrower”), and the undersigned holders (each, a “Holder” and, collectively, the “Holders”). The Company and the Holders are sometimes referred to individually as “Party” and collectively as the “Parties”.
INTERCREDITOR AGREEMENTIntercreditor Agreement • March 15th, 2017 • Fluoropharma Medical, Inc. • In vitro & in vivo diagnostic substances • Nevada
THIS INTERCREDITOR AGREEMENT (the “Agreement”) is dated as of February __, 2017, and is between “Agents” _____________, with an address of _____________________, ________, and __________, with an address of _____________________, ________, and “Participant” or “Participants” on Schedule I attached hereto, with their address set forth opposite their names.
AMENDMENT NO. 3 TO PROMISSORY NOTE OF FLUOROPHARMA MEDICAL, INC.Fluoropharma Medical, Inc. • July 27th, 2016 • In vitro & in vivo diagnostic substances • New York
THIS AMENDMENT NO. 3 TO PROMISSORY NOTE OF FLUOROPHARMA MEDICAL, INC. (this “Amendment”), dated as of July 22, 2016, is made by FluoroPharma Medical, Inc., a Nevada corporation (the “Company” or the “Borrower”), and the undersigned holders (each, a “Holder” and, collectively, the “Holders”). The Company and the Holders are sometimes referred to individually as “Party” and collectively as the “Parties”.
AMENDMENT TO LICENSE AGREEMENT Agreement Number: A220396.01 MGH Case Number: 02155License Agreement • August 15th, 2016 • Fluoropharma Medical, Inc. • In vitro & in vivo diagnostic substances • Delaware
THIS Amendment to the license agreement (the “Amendment”) is effective as of June 1, 2016 (“Amendment Effective Date”), by and between The General Hospital Corporation d/b/a Massachusetts General Hospital, a Not-For-Profit Massachusetts Corporation having a principal place of business at 55 Fruit Street, Boston, Massachusetts 02114 (“Hospital”) and FluoroPharma Medical, Inc., a Delaware corporation, having a principal place of business at 8 Hillside Avenue, Suite 207, Montclair, New Jersey 070433 (“Company”), each referred to herein individually as a “Party” or collectively as the “Parties”.
